The circular RNA developer launched by Flagship Pioneering is developing protein translation lasting months to treat numerous diseases, says CEO Diego Miralles.
In a 3D animation, Laronde illustrates its closed-loop engineered RNA platform, called Endless RNA™ (eRNA). The platform is designed to facilitate longer-lasting protein translation for numerous therapeutic areas and in numerous modalities. [Laronde]
Laronde’s Endless RNA (eRNA) is a versatile synthetic RNA platform designed to instruct cells to express a desired therapeutic protein inside the body. Because eRNA has no free ends, it is not recognized by the immune system and is stable, enabling a longer duration of protein expression than linear RNA. “We're talking about weeks to months,” Laronde CEO Diego Miralles, MD, told GEN Edge
![Phase I AML candidate IPH 2102 works by blocking KIR on natural killer cells.[© Xuejun li - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/July7_2011_23263596_PillsVialsSyringesPennies_BMScollabInnate2304989511-100x70.jpg "BMS Pays Innate Pharma $35M Up Front for Global Rights to Clinical-Stage Cancer mAb")
